PL2054411T3 - Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne - Google Patents

Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne

Info

Publication number
PL2054411T3
PL2054411T3 PL07793254T PL07793254T PL2054411T3 PL 2054411 T3 PL2054411 T3 PL 2054411T3 PL 07793254 T PL07793254 T PL 07793254T PL 07793254 T PL07793254 T PL 07793254T PL 2054411 T3 PL2054411 T3 PL 2054411T3
Authority
PL
Poland
Prior art keywords
isomer
pharmaceutically acceptable
pharmaceutical compositions
acceptable salts
same
Prior art date
Application number
PL07793254T
Other languages
English (en)
Inventor
Sun-Young Kim
Jin Kwan Kim
Ki-Wha Lee
Byoung Young Woo
Song Seok Shin
Joo-Hyun Moh
Sung-Il Kim
Yeon Su Jeong
Kyung Min Lim
Jin Kyu Choi
Jun Yong Ha
Hyun-Ju Koh
Young-Ho Park
Young-Ger Suh
Hee-Doo Kim
Hyeung-Geun Park
Uh Taek Oh
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06015724A external-priority patent/EP1882687A1/en
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Publication of PL2054411T3 publication Critical patent/PL2054411T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL07793254T 2006-07-27 2007-07-26 Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne PL2054411T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP06015724A EP1882687A1 (en) 2006-07-27 2006-07-27 Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
EP06020620 2006-09-29
EP07004194 2007-02-28
US89397407P 2007-03-09 2007-03-09
PCT/KR2007/003592 WO2008013414A1 (en) 2006-07-27 2007-07-26 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP07793254.9A EP2054411B1 (en) 2006-07-27 2007-07-26 Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same

Publications (1)

Publication Number Publication Date
PL2054411T3 true PL2054411T3 (pl) 2015-02-27

Family

ID=38981694

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07793254T PL2054411T3 (pl) 2006-07-27 2007-07-26 Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne

Country Status (10)

Country Link
US (1) US7858621B2 (pl)
EP (1) EP2054411B1 (pl)
JP (1) JP5254228B2 (pl)
KR (1) KR101410318B1 (pl)
AR (1) AR063211A1 (pl)
AU (1) AU2007277519B2 (pl)
CA (1) CA2658925C (pl)
MX (1) MX2009000925A (pl)
PL (1) PL2054411T3 (pl)
WO (1) WO2008013414A1 (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007017884A1 (de) * 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
CN101925575B (zh) * 2008-01-28 2014-06-18 株式会社爱茉莉太平洋 作为香草酸受体拮抗剂的化合物、其异构体或其药物学可接受的盐、及包含这些化合物的药物组合物
SMT201800171T1 (it) 2011-07-29 2018-07-17 Karyopharm Therapeutics Inc Modulatori di trasporto nucleare contenenti idrazide e loro usi
KR102022715B1 (ko) * 2011-07-29 2019-09-18 카리오팜 쎄라퓨틱스, 인코포레이티드 핵 수송 조절인자 및 이의 용도
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
JP6242810B2 (ja) 2011-12-28 2017-12-06 グローバル・ブラッド・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｌｏｏｄ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 置換ベンズアルデヒド化合物および組織酸素化の増加におけるそれらの使用方法
MX364992B (es) 2012-05-09 2019-05-17 Biogen Ma Inc Moduladores del transporte nuclear y usos de los mismos.
MX2015007862A (es) * 2012-12-28 2016-02-05 Nippon Zoki Pharmaceutical Co Derivado de amida del acido cinamico.
EA037091B1 (ru) 2013-03-15 2021-02-04 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
CN105246477A (zh) 2013-03-15 2016-01-13 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
MX379228B (es) 2013-03-15 2025-03-10 Global Blood Therapeutics Inc Compuestos y usos de estos para la modulación de la hemoglobina.
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2803661A1 (en) 2013-05-16 2014-11-19 Lonza Ltd Method for preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives
US9738624B2 (en) 2013-06-21 2017-08-22 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP2818461A1 (en) 2013-06-26 2014-12-31 Lonza Ltd Method for preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives from 4,4,4-trifluoro-3-oxobutanoyl chloride
EP2821398A1 (en) 2013-07-03 2015-01-07 Lonza Ltd Method for preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives from 4,4,4-trifluoro-3-aminobutanoates
EP2821399A1 (en) 2013-07-04 2015-01-07 Lonza Ltd Method for preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives from 4,4,4-trifluoro-3-oxobutanoyl chloride
US9522885B1 (en) 2013-07-19 2016-12-20 Lonza Ltd Method for preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives from trifluoroacetylacetic acid
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
CN114213390A (zh) 2014-02-07 2022-03-22 全球血液疗法股份有限公司 一种化合物的结晶多晶型物
CA2953019A1 (en) 2014-06-26 2015-12-30 Lonza Ltd Method for preparation of 4-alkoxy-1,1,1-trifluorobut-3-en-2- ones from 1,1,1-trifluoroacetone
EP4112615A1 (en) 2014-08-15 2023-01-04 Karyopharm Therapeutics Inc. Compositions comprising one crystalline form of selinexor
KR20160101554A (ko) 2015-02-17 2016-08-25 (주)아모레퍼시픽 N-[4-(1-아미노에틸)-페닐]-메탄술폰아미드 유도체의 카이랄 분할 방법
JP6687596B2 (ja) * 2015-02-17 2020-04-22 アモーレパシフィック コーポレーションＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ Ｎ−［４−（１−アミノエチル）−フェニル］−スルホンアミド誘導体のキラル分割方法
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
KR102359436B1 (ko) * 2015-06-05 2022-02-09 (주)아모레퍼시픽 메틸 2-프로필-6-(트리플루오로메틸) 니코티네이트의 제조방법
KR102287585B1 (ko) 2015-06-30 2021-08-10 (주)아모레퍼시픽 N-(4-아세틸-2,6-디플루오로페닐)메탄술폰아미드의 제조방법
FI3383392T3 (fi) 2015-12-04 2025-09-11 Global Blood Therapeutics Inc Annosteluohjelmat 2-hydroksi-6-((2-(1-isopropyyli-1h-pyratsol-5-yyli)pyridin-3-yyli)metoksi)bentsaldehydille
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
MA43530A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
KR102565407B1 (ko) * 2016-01-04 2023-08-10 (주)아모레퍼시픽 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
TWI752307B (zh) 2016-05-12 2022-01-11 美商全球血液治療公司 新穎化合物及製造化合物之方法
KR102599958B1 (ko) 2016-09-28 2023-11-09 (주)아모레퍼시픽 (r)-n-[4-(1-아미노-에틸)-2,6-다이플루오로-페닐]-메테인설폰아마이드의 제조방법
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
KR102587339B1 (ko) 2016-12-22 2023-10-12 (주)아모레퍼시픽 N-[4-(1-아미노-에틸)-2,6-다이플루오로-페닐]-메테인설폰아마이드의 거울상 이성질체들의 라세미화 방법
EP3666254B1 (en) 2017-08-11 2024-12-04 Amorepacific Corporation Pharmaceutical composition containing (r)-n-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
WO2019045215A1 (ko) 2017-08-31 2019-03-07 (주)아모레퍼시픽 수면장애 예방 또는 치료용 조성물
KR102587300B1 (ko) 2017-08-31 2023-10-12 (주)아모레퍼시픽 아토피피부염 예방 또는 치료용 조성물
KR102587297B1 (ko) 2017-08-31 2023-10-12 (주)아모레퍼시픽 수면장애 예방 또는 치료용 조성물
KR102518632B1 (ko) * 2018-04-18 2023-04-06 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
KR20200053746A (ko) 2018-11-09 2020-05-19 (주)아모레퍼시픽 졸-겔 조성물
EP3911649A1 (en) * 2019-01-17 2021-11-24 F. Hoffmann-La Roche AG A process for the preparation of tetrahydropyridopyrimidines
CA3152770A1 (en) * 2019-08-30 2021-03-04 National University Of Singapore N-(2-aminophenyl)-prop-2-enamide derivatives, and uses thereof in the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1303483B1 (en) 2000-08-21 2008-04-23 Pacific Corporation Novel thiourea derivatives and the pharmaceutical compositions containing the same
EP1311478B1 (en) * 2000-08-21 2006-06-07 Pacific Corporation Novel (thio)urea compounds and the pharmaceutical compositions containing the same
MY138086A (en) * 2001-09-13 2009-04-30 Smithkline Beecham Plc Novel urea derivative as vanilloid receptor-1 antagonist
MXPA04005427A (es) * 2001-12-10 2005-04-19 Amgen Inc Ligandos de receptor vainilloide y su uso en tratamientos.
KR100707123B1 (ko) * 2003-07-02 2007-04-16 그뤼넨탈 게엠베하 바닐로이드 수용체의 길항제로서 강력한 진통효과를나타내는 4-(메틸설포닐아미노)페닐 동족체 및 이를함유하는 약학적 조성물
JP2007509846A (ja) * 2003-10-15 2007-04-19 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−ナフタレンおよび尿素誘導体
JP4799562B2 (ja) * 2004-11-10 2011-10-26 ファイザー株式会社 置換ｎ−スルホニルアミノベンジル−２−フェノキシアセトアミド化合物
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物
DE602006009231D1 (de) 2005-03-10 2009-10-29 Pfizer Substituierte n-sulfonylaminophenylethyl-2-phenoxyacetamidverbindungen
WO2006098554A1 (en) 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
CN101160285A (zh) 2005-03-17 2008-04-09 辉瑞大药厂 适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物
AU2006225496A1 (en) 2005-03-19 2006-09-28 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
JP2009536657A (ja) * 2006-05-10 2009-10-15 レノビス， インコーポレイテッド イオンチャンネルリガンドとしてのアミド誘導体およびそれを用いる医薬組成物および方法

Also Published As

Publication number Publication date
AU2007277519A1 (en) 2008-01-31
KR20090033916A (ko) 2009-04-06
US7858621B2 (en) 2010-12-28
EP2054411A4 (en) 2010-07-07
CA2658925A1 (en) 2008-01-31
CA2658925C (en) 2015-07-14
JP2009544696A (ja) 2009-12-17
AR063211A1 (es) 2009-01-14
WO2008013414A1 (en) 2008-01-31
JP5254228B2 (ja) 2013-08-07
US20080312234A1 (en) 2008-12-18
KR101410318B1 (ko) 2014-06-27
EP2054411A1 (en) 2009-05-06
EP2054411B1 (en) 2014-08-20
MX2009000925A (es) 2009-02-05
AU2007277519B2 (en) 2011-12-22

Similar Documents

Publication Publication Date Title
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
PL2079688T3 (pl) Antagoniści receptora glukagonu, kompozycje zawierające takie związki oraz ich zastosowanie farmaceutyczne
IL185891A0 (en) Novel compounds and their isomers and pharmaceutical compositions containing the same as vanilloid receptor antagonists
IL192298A (en) Heterocyclic Compounds, Their Acceptable Salts, Pharmaceuticals Containing and Using Them
IL197933A (en) Knaase inhibitors, pharmaceuticals containing them and their uses
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
LT2046298T (lt) Farmacinė vaisto forma, turinti farmaciniu požiūriu priimtiną soliubilizuojančią kompoziciją
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
IL193894A0 (en) Pharmaceutical compositions containing luliconazole for external use
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
EP2039366A4 (en) COMPOSITION CONTAINING PEPTIDE AS ACTIVE INGREDIENT
PL2364983T3 (pl) Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
IL195528A (en) Pyridazine compound, methods of preparation, a pharmaceutical composition containing it, its use and intermediate material
IL169575A0 (en) Calcium-sensing receptor antagonist compounds and pharmaceutical compositions containing the same
WO2007031933A3 (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
WO2007050802A3 (en) Novel opioid antagonists
IL198780A0 (en) Pharmaceutical formulation comprising neurokinin antagonist
IL177665A0 (en) Novel pharmaceutical compositions comprising agonists of the thyroid receptor
ZA200705363B (en) Pharmaceutical compositions comprising amorphous benzimidazole compounds
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
EP2201011A4 (en) NEW COMPOUNDS WITH INDAZOUS OUTS, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
PL2231598T3 (pl) Nowe pochodne diazeniodiolanów, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
ZA200606606B (en) Substituted Azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
WO2010131192A3 (en) Novel oxazolidinone derivatives and their use as orexin receptor antagonists